• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Zealand Pharma A/S ADR (NQ: ZEAL )

    N/A UNCHANGED
    Last Price Updated: 3:24 PM EDT, Sep 29, 2022 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 8.820 (2)
    Ask (Size) 20.00 (2)
    Prev. Close 17.59
    Today's Range N/A - N/A
    52wk Range N/A - N/A
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
    From Zealand Pharma
    Via GlobeNewswire

    Performance

    More News

    Read More
    Zealand Pharma major shareholder announcement: Polar Capital
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma major shareholder announcement: Van Herk Investments
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher
    Via Benzinga
    Recap: Zealand Pharma Q1 Earnings
    Via Benzinga
    Zealand Pharma completes registration of capital increase
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares
    From Zealand Pharma
    Via GlobeNewswire
    Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
    Via Benzinga
    Total number of shares and voting rights in Zealand Pharma at September 30, 2022
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels
    Via Benzinga
    Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
    Via Benzinga
    Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
    Via Benzinga
    Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
    Via Benzinga
    71 Biggest Movers From Yesterday
    Via Benzinga
    Mid-Afternoon Market Update: Dow Falls 150 Points; NeuroMetrix Shares Spike Higher
    Via Benzinga
    38 Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Zealand Pharma Shares Are Rising
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.